Who is sponsoring NCT05437276?

NCT05437276 is sponsored by Helius Medical Inc.

What drugs are being tested in NCT05437276?

Interventions in NCT05437276: PoNS®.

What condition does NCT05437276 study?

NCT05437276 studies Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS).

Is NCT05437276 still recruiting?

NCT05437276 is currently completed. Last updated 28 March 2025.

Last reviewed 2025-03-28 · How we verify

NCT05437276: PoNSTEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)

Completed Last updated 28 March 2025

What this trial tests

trial testing PoNS® in Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS) in 43 participants. Completed in 31 December 2024.

Timeline

1 July 2022

Primary endpoint
30 June 2024

31 December 2024

Quick facts

Lead sponsor	Helius Medical Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	43
Start date	1 July 2022
Primary completion	30 June 2024
Estimated completion	31 December 2024
Sites	5 locations across United States

Drugs / interventions tested

PoNS®

Conditions studied

Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS) — all drugs for Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS) →

Sponsor

Helius Medical Inc

Who can join

22 and older, any sex, with Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PoNS therapy is a rehabilitation program that uses the PoNS device in conjunction with individualized physical exercise. This is an outcome research open label observational interventional multi-center study investigating the relationship between subject's adherence to PoNS therapy and therapeutic outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Helius Medical Inc trials

Trials by the same sponsor.

NCT06470009 — Portable Neuromodulation Stimulator (PoNS®) Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Randomi · NA · active not recruiting
NCT06336720 — PoNS® Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Single-Arm Study · NA · active not recruiting
NCT06930339 — Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis · active not recruiting
NCT03732755 — PoNS Clinical Experience Program (TBI) · NA · unknown
NCT03852732 — PoNS Clinical Experience Program (TBI) · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05437276 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Helius Medical Inc
Last refreshed: 28 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing